Oncogenic pathway signatures predict the risk of progression and recurrence in well-differentiated pancreatic neuroendocrine tumors

By sjmartinez • August 19, 2024

Mederos MA, Court CM, Dipardo BJ, Pisegna JR, Dawson DW, Joe Hines O, Donahue TR, Graeber TG, Girgis MD, Tomlinson JS. Oncogenic pathway signatures predict the risk of progression and recurrence in well-differentiated pancreatic neuroendocrine tumors. J Surg Oncol. 2024 Aug 19. doi: 10.1002/jso.27830. Epub ahead of print. PMID: 39155697.

Tags: Digestive Diseases, genomic biomarker, pancreatic neuroendocrine tumor, prognosis, Publications, recurrence, Veterans Administration, whole‐exome sequencing

Distinct risk groups with different healthcare barriers and acute care use exist in the U.S. population with chronic liver disease

Wong CR, Crespi CM, Glenn B, Han SB, Macinko JA, Bastani R. Distinct risk groups with different healthcare barriers and acute care use exist in[...]

Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?

Gukovskaya AS, Lerch MM, Mayerle J, Sendler M, Ji B, Saluja AK, Gorelick FS, Gukovsky I. Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?[...]

Stricturing Crohn’s Disease: When Biologics May Help or Not?

Fansiwala K, Limketkai BN. Stricturing Crohn's Disease: When Biologics May Help or Not? Inflamm Bowel Dis. 2024 Nov 12:izae264. doi: 10.1093/ibd/izae264. Epub ahead of print.[...]